

# WT1 Expression in Reactive and Neoplastic Glial Cells as a New Diagnostic Tool

Salwa Ibrahim El Haddad, Nahed Samy Khamis, Riham M. Abu-Zeid, Wesam Mohammed Osman, Salma Tarek Mahmoud Hafez\*

*Department of Pathology, Faculty of Medicine, Ain Shams University, Faculty of Dentistry\*, MSA University\*, Cairo, Egypt*

## Corresponding author

Name: Salma Tarek Mahmoud Hafez

Scientific degree: Assistant Lecturer of Pathology.

Affiliation: Faculty of Dentistry - MSA University.

E-mail: [stmh099@gmail.com](mailto:stmh099@gmail.com)

Mobile: 01271000946

## ABSTRACT

**Background:** Glial tumors are the most common primary brain tumors. The majority of glial tumors are malignant. In small brain biopsies, morphological features of astrocytic neoplasms overlap with reactive astrogliosis occurring within or around brain lesions of various etiologies. So far no immunohistochemical marker allows a reliable distinction and this may result in a diagnostic dilemma. The Wilms' tumor suppressor gene (WT1) encodes for a zinc-finger transcription factor. The WT1 protein is involved in proliferation, differentiation and apoptosis. Interaction with other transcription factors like EGR-1 and p53 shows that WT1 has oncogenic properties.

**Objective:** To evaluate retrospectively the immunohistochemical expression of WT1 in reactive and neoplastic glial cells.

**Material & methods:** This retrospective study included 55 cases, 45 cases of which were previously diagnosed as glial tumors (astrocytomas, oligodendrogliomas and ependymomas) and 10 cases as reactive brain tissue (5 cases of reactive brain tissue adjacent to metastatic tumors and 5 cases of reactive gliosis). The cases were received at the Pathology Department of Ain Shams University Hospital and Ain Shams Specialized Hospital. Immunohistochemistry using Anti-WT1 a mouse monoclonal antibody, Clone 6F-H2 was performed to detect the expression of WT1 (cytoplasmic staining) which was in turn correlated with clinico-pathological factors.

**Results:** Immunohistochemical staining of WT1 expression was cytoplasmic within glial neoplastic cells and negative in reactive glial cells. There was a highly significant difference statistically between WT1 expression in cases of gliosis and different WHO grades ( $P < 0.01$ ). Cases of glial tumors were positive with variable scores. WT1 immunostaining revealed significant positive relationship between grade and score, ( $P < 0.001$ ).

**Conclusion:** WT1 can be used to differentiate normal astrocytes from neoplastic cells. WT1 not only plays a role in neoplastic transformation of astrocytic cells, but also may have a key role in progression and aggressive transformation of astrocytic tumors where it might be one of the switches for the emergence of GBM. Over-expression of WT1 in astrocytic brain tumors, especially high-grade types, suggests that WT1 could be a suitable target for cancer immunotherapy.

**Keywords:** Gliosis, Glial tumors, GBM (Glioblastoma Multiform), WT1 Immunohistochemistry.

# **WT1 Expression in Reactive and Neoplastic Glial Cells as a New Diagnostic Tool**

## **Thesis**

**Submitted for partial fulfillment of M.D. Degree in Pathology**

**By**

**Salma Tarek Mahmoud Hafez**

M.sc

Faculty of Medicine,  
Cairo University

## **Under supervision of**

**Prof. Dr. Salwa Ibrahim El Haddad**

Professor of Pathology,  
Faculty of Medicine,  
Ain Shams University

**Prof. Dr. Nahed Samy Khamis**

Head of Pathology Department,  
Faculty of Medicine,  
Ain Shams University

**Prof. Dr. Riham M. Abu-Zeid**

Professor of Pathology,  
Faculty of Medicine,  
Ain Shams University

**Prof. Dr. Wesam Mohammed Osman**

Professor of Pathology,  
Faculty of Medicine,  
Ain Shams University

**Faculty of Medicine  
Ain Shams University**

**2016**

# Acknowledgements

*First of all thanks to **ALLAH** who gave me the opportunity to start this work and also give me the strength and power to complete it in the best way I could.*

*My deepest gratitude, profound gratefulness and thanks go to my Professors of pathology, Faculty of Medicine, Ain Shams University, namely **Prof. Dr. Safwa Ibrahim EL Haddad** for her guidance and shedding light on different points of discussion.*

***Prof. Dr. Nahed Samy Khamis**, Head of Pathology Department, who devoted a great deal of her time to me in clarifying several important points and shaping the essential concepts to be presented into articulate form.*

***Prof. Dr. Riham Mohamed Abu Zeid**, for her generous cooperation, assistance and her sincere comments and ideas which I made use of.*

***Prof. Dr. Wesam Mohammed Osman**, for her generous assistance as she played a major part in the development and revision of this work.*

***Prof. Dr. Nedal Hegazy**, as the director of Pathology unit of Ain Shams specialized hospital and her team work for facilitating the collection of the material and finishing the practical part of the study.*

*Lastly, I would like to dedicate this work to my grandfather **Prof. Dr Mahmoud Hafez**, my supporting **Family** who played a pivotal role in every success I achieved and also my **Husband** who encouraged and helped me throughout all the work and to my beloved boys.*

# List of Contents

<b>Title</b>	<b>Page</b>
<b>List of abbreviations</b>	<b>i</b>
<b>List of tables</b>	<b>ii</b>
<b>List of graphs</b>	<b>iv</b>
<b>List of figures</b>	<b>v</b>
<b>Introduction</b>	<b>1</b>
<b>Aim of the study</b>	<b>4</b>
<b>Review of Literature</b>	<b>5</b>
• <i>Glios</i>	<b>5</b>
• <i>Glial Tumors</i>	<b>19</b>
• <i>WT1</i>	<b>83</b>
<b>Materials and Methods</b>	<b>92</b>
<b>Results</b>	<b>97</b>
<b>Discussion</b>	<b>141</b>
<b>Summary</b>	<b>153</b>
<b>Conclusion and recommendation</b>	<b>156</b>
<b>References</b>	<b>158</b>
<b>Arabic Summary</b>	<b>--</b>

## List of abbreviations

Abbreviation	Name
AA	Anaplastic astrocytoma
BTSC	Brain tumor stem cells
CNS	central nervous system
CSF	Cerebrospinal fluid
CT	Computed tomography
EGFR	Epidermal growth factor receptor
FLAIR	Fluid attenuation inversion recovery
GFAP	Glial fibrillary protein
IHC	immunohistochemistry
IARC	International agency for research on cancer
LOH	Loss of heterozygosity
MRI	Magnetic resonance imaging
NCI	National Cancer Institute
NF-1	Neurofibromatosis type 1
NF-2	Neurofibromatosis type 2
PTEN	Phosphatase and tensin homolog
PI3K	Phosphatidyl inositol 3 kinase
P53	Protein weighing 53 kildaltons
VEGF	Vascular endothelial growth factor
WT1	Wilm's tumor-1
WHO	World health organization

## List of Tables

Table	Title	Page
1	The 2016 World Health Organization Classification of Tumors of the Central Nervous System.	27
2	World Health Organization Criteria for Grading of Astrocytomas.	30
3	Distribution of studied cases according to age.	97
4	Distribution of studied cases according to site.	98
5	Histological subtypes.	99
6	Distribution of studied cases according to grade.	100
7	Mean age of different grades of glial tumors.	101
8	Distribution of sex among glial tumors.	102
9	Distribution of tumor type according to site.	103
10	Distribution of different astrocytoma grades according to site.	103
11	Correlation between WT1 expression and age of cases of glial tumors.	106
12	Correlation between WT1 expression and gender of cases of glial tumors.	107
13	Mean WT1 expression in different sites of brain tumors.	108
14	Distribution of WT 1 staining (scoring) among studied cases of gliosis.	109
15	WT1 expression in different pathological types of glial tumors.	109

## List of Tables (Cont.)

<b>Table</b>	<b>Title</b>	<b>Page</b>
16	WT 1 staining score among various grades of astrocytomas.	111
17	Comparison between cases with gliosis and different WHO grades as regards the WT1 mean scores.	113
18	Correlation of WT 1 expression in gliosis and different WHO grades of astrocytic brain tumors.	115
19	WT 1 staining (scoring) among various grades of oligodendroglioma.	116
20	Distribution of WT1 staining(scoring) among various grades of studied cases of ependymoma.	117

## List of Graphs

Graph	Title	Page
1	Distribution of studied cases according to age.	97
2	Distribution of studied cases according to sex.	98
3	Distribution of studied cases according to site.	98
4	Distribution of studied cases according to histological subtypes.	99
5	Distribution of studied cases according to grade.	100
6	Distribution of sex among glial tumors.	102
7	Distribution of different astrocytoma grades according to site.	104
8	Correlation between WT1 expression and age of cases of glial tumors.	106
9	Correlation between WT1 expression and gender of cases of glial tumors.	107
10	Mean WT1 expression of different sites of brain tumor	108
11	Mean WT1 expression scores in different pathological types of glial tumors.	110
12	WT 1 immunohistochemical expression among various grades of studied cases of astrocytoma	112
13	Comparison between cases with gliosis and different WHO grades as regards the WT1 mean scores.	113
14	Correlation curve between Grades of astrocytic tumors and WT1 expression.	115
15	WT 1 immunohistochemical expression among various grades of oligodendroglioma.	116
16	WT1 immunohistochemical expression among grades of ependymoma.	117



## List of Figures

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
1	The “glia.” A, Fibrous astrocytes (GFAP). B, Oligodendroglia, H&E C, Ependymal cells H&E. D, Microglia H&E.	10
2	Gliosis. A,H&E (gemistocytic) appearance in early tissue reactions. B, Glial fibrillary acidic protein (GFAP) C, Later stages H&E D, The Alzheimer type II cell H&E E, (piloid gliosis) H&E F, Extensive piloid gliosis H&E	13
3	Cerebellar pilocytic astrocytoma MRI	33
4	Pilocytic astrocytoma H&E	35
5	Pilomyxoid astrocytoma H&E	40
6	Diffuse astrocytoma (grade II) MRI	42
7	Diffuse astrocytoma(grade II) H&E	44
8	Anaplastic astrocytomas H&E	48
9	Glioblastoma MRI	52
10	Glioblastoma (tissue patterns)H&E	57
11	Glioblastoma types H&E	60
12	Anaplastic oligodendroglioma (grade III) MRI	67
13	istological features of oligodendroglioma (H&E).	69
14	Oligoastrocytoma H&E.	70
15	Ependymomas H&E	78
16	Ependymomas H&E	78
17	Uterine papillary serous carcinoma WT1	90
18	Ovarian serous carcinomaWT1	91

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
19	Gliosis showing reactive astrocytes which tend to be evenly distributed within the tissue (Haematoxlyin and eosin staining x100)	118
20	Gliosis showing reactive astrocytes which tend to be evenly distributed within the tissue with a fibrillary background (Haematoxlyin and eosin staining x200)	118
21	Gliosis with WT1immunoexpression restricted to endothelial lining of capillaries, no WT1 expression in glial cells, score 0.(WT 1 immunostaining x100)	119
22	Gliosis showing the same pattern of immunostaining expression of WT1 mentioned above, score 0.(WT 1immunostaining x200)	119
23	Pilocytic astrocytoma grade I showing microcystic areas(arrow) (Haematoxlyin and eosin staining x100)	120
24	Pilocytic astrocytoma grade I showing microcystic areas(arrow),cells posses round to oval cytologically bland nuclei, a small cell body and relatively short hair like processes (Haematoxlyin and eosin staining x200)	120
25	Pilocytic astrocytoma grade I showing compact portions with parallel bundles of elongated fibrillary cytoplasmic process resembling mats of hair and cork-screw shaped bodies (Rosenthal fibers) arrow(Haematoxlyin and eosin staining x100)	121

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
26	Pilocytic astrocytoma grade I with positive WT 1 immunoexpression (arrow), score 2 (WT1 immunostaining x100)	121
27	Pilocytic astrocytoma grade I with positive WT 1 immunoexpression, Score 2 (WT1 immunostaining x400)	122
28	Diffuse fibrillary astrocytoma grade II showing increase cellularity with scattered gemistocytes (arrow) (eosinophilic cell body and eccentric nuclei) (Haematoxylin and eosin staining x400)	122
29	Diffuse astrocytoma grade II with positive WT 1 immunoexpression, score 1 (WT1 immunostaining x100)	123
30	Diffuse fibrillary astrocytoma grade II with positive WT1 immunoexpression, score 1 (WT1 immunostaining x400)	123
31	Gemistocytic rich astrocytoma grade II with positive WT 1 immunoexpression, score 3 (WT1 immunostaining x400)	124
32	Anaplastic astrocytoma grade III showing increased cellularity with nuclear pleomorphism and hyperchromasia (Haematoxylin and eosin staining x200).	124
33	Anaplastic astrocytoma grade III (Haematoxylin and eosin staining x400).	125
34	Anaplastic astrocytoma grade III showing increased cellularity with nuclear pleomorphism and hyperchromasia and occasional gemistocytes (Haematoxylin and eosin staining x400).	125

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
35	Anaplastic astrocytoma grade III with positive WT1 immunoexpression with WT1 negative areas (arrow), score 3 (WT1 immunostaining x200)	126
36	Anaplastic astrocytoma grade III with positive WT1 immunoexpression, score 3 (WT1 immunostaining x200)	126
37	Anaplastic astrocytoma grade III with positive WT1 immunoexpression, score 3 (WT1 immunostaining x400)	127
38	GBM grade IV showing increased cellularity with prominent microvascular proliferation (Haematoxylin and eosin staining x100).	127
39	GBM grade IV showing increased cellularity with prominent microvascular proliferation (Hematoxylin and eosin staining x200).	128
40	GBM grade IV showing increased cellularity, prominent microvascular proliferation (Hematoxylin and eosin staining x200).	128
41	Higher power view of previous case (Haematoxylin and eosin staining x400).	129
42	GBM grade IV showing pseudopalisading necrosis (Haematoxylin and eosin staining x100).	129
43	GBM grade IV showing pseudopalisading necrosis (small irregularly shaped band like foci surrounded by radially oriented densely packed small fusiform astrocytes (Hematoxylin and eosin staining x200).	130

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
44	GBM grade IV with positive WT1 immunoexpression, score 4 (WT1 immunostaining x200)	130
45	GBM grade IV with positive WT1 immunoexpression score 4(WT1 immunostaining x200)	131
46	GBM grade IV with positive WT1 immunoexpression, score 3 (WT1 immunostaining x200)	131
47	GBM grade IV with positive WT1 immunoexpression, score 3 in area of palisading surrounding necrosis(with weaker immunostaining), (WT1immunostaining x200)	132
48	GBM grade IV with positive WT1 immunoexpression, score 2(WT1 immunostaining x 200)	132
49	GBM grade IV with positive WT1 immunoexpression score 3(WT1 immunostaining x400)	133
50	Oligodendroglioma grade II showing moderate cellularity composed of monomorphic cells with uniform round nuclei and perinuclear halos(fried egg appearance) (Haematoxlyin and eosin staining x200).	133
51	Oligodendroglioma grade III showing increased cellularity with prominent microvascular proliferation (Haematoxlyin and eosin staining x100).	134

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
52	Oligodendroglioma grade III showing increased cellularity with increased nuclear pleomorphism and prominent microvascular proliferation (Haematoxylin and eosin staining x200)	134
53	Oligodendroglioma grade II with positive WT1 immunoexpression, score 2 (WT1 immunostaining x100)	135
54	Anaplastic oligodendroglioma grade III with positive WT1 immunoexpression, score 1 (WT1 immunostaining x200)	135
55	Anaplastic oligodendroglioma grade III with positive WT1 immunoexpression, score 1(WT1 immunostaining x400)	136
56	Anaplastic oligodendroglioma grade III with positive WT1 immunoexpression, score 3(WT1 immunostaining x200).	136
57	Ependymoma grade III with increased cellularity showing true rosettes(arrows) (Haematoxylin and eosin staining x200)	137
58	Ependymoma grade III showing increased cellularity, increased nuclear pleomorphism (Haematoxylin and eosin staining x400)	137
59	Ependymoma grade III showing increased cellularity, increased nuclear pleomorphism and prominent microvascular proliferation (arrow) (Haematoxylin and eosin staining x400)	138

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
60	Ependymoma grade II, showing score 1(WT 1 immunostaining x200)	138
61	Ependymoma grade II, showing score 1(arrows)(WT 1 immunostaining x400)	139
62	Ependymoma grade III with positive WT1 immunoexpression, score 3(WT 1 immunostaining x200)	139
63	Ependymoma grade III with positive WT1 immunoexpression, score 3(WT 1 immunostaining x200)	140